US court dismisses Cygnus lawsuit:
This article was originally published in Clinica
The US Court of Appeals has upheld a 1995 decision to dismiss Cygnus' action against Alza (see Clinica No 589, p 12). Cygnus had sought a declaratory judgement of invalidity and/or unenforceability of Alza's patent relating to transdermal administration of fentanyl. The court dismissed Cygnus' case on jurisdictional grounds, rather than the merits of the argument says Gregory Lawless, Cygnus' CEO and president, says.
You may also be interested in...
Lilly has launched a similar antibody product, but demand is expected to outpace supply for the foreseeable future.
Perrigo, Pfizer want the US FDA to postpone its March 1 deadline for conducting nitrosamine risk assessments. Generics exec cites“serious compliance challenges” in conducting these assessments due to difficulty in finding the right lab equipment necessary to quantify nitrosamine daily intake limits.
Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.